Lantern Pharma is a clinical stage biotechnology company focused on innovating the cancer drug development process by using advanced genomics, machine learning, and artificial intelligence ("A.I."). Our A.I. platform, known as RADR®️, currently includes more than 60 billion data points, and uses big data analytics and machine learning to rapidly uncover biologically relevant genomic signatures correlated to drug response, and then to identify the cancer patients that we believe may benefit most from our compounds. RADR®️ is also used by Lantern and its collaborators to 1) develop and position new drugs and 2) to rescue and reposition drug candidates that others have tried, but failed, to develop.
Lantern’s current portfolio consists of four drug candidates and an ADC program across eleven disclosed tumor targets, including two Phase 2 programs and several additional Phase 1 clinical trials anticipated for 2023. Lantern seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to assist with its objective of delivering cancer therapies to patients as quickly and cost-effectively as possible. This data-driven, genomically-targeted and biomarker-driven approach allows us to pursue a transformational drug development strategy that identifies, rescues or develops, and advances potential small molecule drug candidates at what we believe is a fraction of the time and cost associated with traditional cancer drug development.
